%0 Journal Article %T Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine %A Katoh, Masaru %J Journal of Thoracic Disease %D 2018 %B 2018 %9 %! Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine %K %X Therapeutics targeting epigenetic regulators (1-3), immune modulators (4-6) and receptor tyrosine kinases (7-9) have emerged as promising drugs for cancer patients who are refractory to conventional chemotherapy, radiotherapy or surgery ( Figure 1 ). These cutting-edge therapeutics, together with next-generation sequencing (NGS) technologies that produce bulk genomics-related data as commodities of clinical medicine, have led to a gradual shift toward personalized or precision medicine. %U https://jtd.amegroups.org/article/view/19778 %V 10 %N 3 %P 1294-1299 %@ 2077-6624